Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDMA advocates label reform through expansion of FDA's flexibility policy.

This article was originally published in The Tan Sheet

Executive Summary

NDMA URGING LABEL REFORM THROUGH "FLEXIBILITY POLICY" EXPANSION, Senior VP-Science and Technology William Soller, PhD, declared at a Sept. 29 FDA public hearing on OTC labeling. The policy, adopted by FDA in 1986, allows the use of alternate, non-monograph wording in the Indications and Directions sections of OTC labels so long as the statements are truthful and not misleading. The policy states that "within limits, there can be various ways of accurately stating the same thing, some of which may even be more meaningful" than the monograph language.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel